Immuron (ASX:IMC) reported global sales for its immune supplement, Travelan, of roughly AU$2.5 million in the December 2024 quarter, a surge of 249% year on year, according to a Friday filing with the Australian bourse.
Sales in Australia soared 315% to nearly AU$1.9 million, while North American sales climbed 141% to AU$652,000.
Global half-year sales jumped 70% to AU$4 million.
The biopharmaceutical company's shares climbed past 8% in recent Friday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。